I.M. has received research grants from Alligator, Bioncotech, Bristol Myers Squibb (BMS), Leadartis, Pfizer and Roche; has received speaker’s bureau honoraria from MSD; and is a consultant or advisory board member for Alligator, AstraZeneca, Bayer, Bioncotech, BMS, F-Star, Genmab, Gossamer, Merck Serono, Numab, Pieris and Roche. E.C. is a consultant or advisory board member for AstraZeneca, Beigene, BMS, MSD and Roche. S.C. has received honoraria from Amgen, AstraZeneca, BMS, Janssen, Merck, MSD, Novartis and Roche; is an advisory board member for Amgen and AstraZeneca; has received funding for travel and conference attendance from AstraZeneca, MSD and Roche; and has received research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen-Cilag, Merck, Novartis, Onxeo, Pfizer, Roche and Sanofi, and non-financial research support (investigational drugs) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Medimmune, Merck, NH TherAGuiX, Onxeo, Pfizer and Roche. S.C. has been a principal investigator of academic or industry-sponsored clinical trials of intratumoural immunotherapies for Abbvie, AstraZeneca/Medimmune, BMS, Eisai/H3 Biomedicine, IDERA, Lytix Biopharma, MSD, Nanobiotix and Sanofi/BioNTech. A.M. has been a principal investigator of academic or industry-sponsored clinical trials of intratumoural immunotherapies from AstraZeneca, BMS, Eisai, IDERA, Lytix Biopharma, Merck/MSD, Roche and Transgene; is a member of the Data Safety and Monitoring Board of a trial of a intratumoural TLR3 agonist sponsored by Oncovir (NCT02423863); and has participated in scientific advisory boards or has provided consultancy services on the topic of intratumoural immunotherapies for Amgen, AstraZeneca, Banque Pour l’Investissement, Bayer, Eisai, eTheRNA, Lytix Biopharma, Medincell, MSD, Novartis, Oncosec, Pillar Partners, Rigontec and Sanofi/BioNTech. M.A. declares no competing interests.
PubMed
